Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
REGENXBIO develops gene therapies for genetic diseases and licenses its technology to other biotech and pharmaceutical companies.
REGENXBIO is a gene therapy company. It owns a library of harmless viruses — mostly a type called AAV — that it engineers to carry working copies of genes into a patient's cells. The idea is simple to say and hard to do: if a disease is caused by a broken gene, deliver a working version of that gene and let the body's own cells do the repair work. The company uses this platform both to develop its own treatments and to hand the technology to larger partners.
Its main money engine is licensing. REGENXBIO grants rights to its NAV Technology Platform to other biotech and drug companies, who pay it upfront fees, milestone payments as programs advance, and royalties on sales if a product reaches the market. Its most famous relationship is with Novartis, which used the platform in Zolgensma, a gene therapy for spinal muscular atrophy in young children. That royalty stream matters because it is revenue that arrives without REGENXBIO spending its own cash on a giant sales force. The company also runs its own pipeline, with programs aimed at eye diseases, neuromuscular conditions, and metabolic disorders. The appeal to partners is time and risk. Building a gene-delivery system from scratch takes years and huge spending, so licensing a proven platform lets a big drugmaker skip the earliest, messiest science. The catch is that REGENXBIO depends heavily on a small number of partners and on clinical trials succeeding — if a partner's program stumbles or a royalty-bearing drug sells poorly, the money shrinks. Gene therapy is also a brutal field: manufacturing is complex, treatments are expensive, and regulators scrutinize safety closely, especially after reports of serious side effects in the wider AAV field.
REGENXBIO is based in Rockville, Maryland, part of the biotech cluster around Washington. It is a clinical-stage, loss-making company, which means it burns cash on research and relies on its balance sheet, licensing income, and occasionally raising new money to keep going. Watching it comes down to a few things: how its partners' programs progress, whether its own trials produce good data, and whether it can turn its scientific platform into approved medicines rather than just promises.
Saved answer · last researched 15 Nov 2026